U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07799441) titled 'Neurovascular Effects of Empagliflozin' on Aug. 26.
Brief Summary: The goal of this clinical trial is to examine whether empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, improves vascular and autonomic function in adults with prehypertension. The main questions this clinical trial aims to answer are:
1. Does empagliflozin improve endothelial function?
2. Does empagliflozin improve sympathetic nervous system function?
This clinical trial employs a double-blind, placebo-controlled crossover study lasting up to 6 weeks for participants with prehypertension and up to 2 weeks for normotensive participants. Participa...